 |
市场调查报告书
商品编码
1427218
全球细胞增殖市场规模、份额、成长分析、按产品、按细胞类型 - 产业预测 2023-2030Global Cell Expansion Market Size, Share, Growth Analysis, By Product(Consumables, Culture Flasks & Accessories), By Cell Type(Mammalian, Microbial) - Industry Forecast 2023-2030 |
||||||
2022年全球细胞增殖市场规模为252.1亿美元，从2023年的276亿美元扩大到2031年的570.6亿美元，复合年增长率预计将成长9.5%。
市场驱动因素之一是越来越多地采用自动化解决方案，特别是在细胞增殖应用中，例如基因疗法、细胞疗法产品 (CTP) 和其他生技药品，以提高程序的可靠性。这会导致成本和劳动力的增加节省开支的同时提高生产力。在CTP 生产中转向一次性系统(SUS) 消除了由于灭菌不充分而导致的交叉污染和培养物污染的风险，从而实现长期成本节约并以更高的细胞密度生产CTP，从而提供了显着的製造优势。 SUS 采用率的快速成长将刺激 CTP 的发展并进一步促进市场扩张。同时，在商业和公共组织资金增加以及加速倡议进展的措施的推动下，生命科学领域对细胞疗法的兴趣日益浓厚。国际干细胞研究学会等组织正积极为干细胞相关研究应用寻求资金，确保细胞增殖的技术进步和产品创新为市场带来重大经济机会，有望带来成功。然而，缺乏先进设备和3D细胞扩增技术可能成为市场扩张的障碍。
使用自上而下和自下而上的方法来估计和检验全球细胞增殖市场的规模，并估计其他各个相关子市场的规模。用于估计市场规模的调查方法包括以下细节：二级研究用于确定市场中的主要企业，一级和二级研究用于确定每个地区的市场占有率。整个过程包括研究主要企业的年度和财务报告以及广泛的采访，以获得执行长、副总裁、董事和行销负责人等行业领导者的重要见解。所有股份比率和细分均使用二手资讯确定并使用主要资讯检验。本研究涵盖的所有可能影响市场的参数都经过广泛而详细的考虑，透过初步研究检验并进行分析，以获得最终的定量和定性资料。
细胞增殖全球细分市场分析
全球细胞增殖市场根据产品、最终用途、细胞类型和地区进行细分。依产品划分，市场分为消耗品、培养瓶及配件、仪器。依最终用途，市场分为生物製药、研究机构、细胞库等。依细胞类型，市场分为哺乳动物、微生物和其他。依地区划分，分为北美、欧洲、亚太地区、中东/非洲、拉丁美洲。
全球细胞增殖市场的驱动因素
CRISPR/Cas9 等基因工程的进步简化了为高效蛋白质表现而客製化的优质细胞株的创建。这些尖端工具能够精确调整细胞基因组、提高蛋白质产量、完善细胞製程并提高产品标准。仔细表征和高产细胞株的存在是扩大细胞表现领域的主要驱动力。
全球细胞增殖市场的限制因素
表达系统细胞株的产生通常依赖动物或人类来源的细胞，导致伦理困境。围绕动物福利、人类细胞的道德来源以及胚胎干细胞的使用的担忧可能会限制某些细胞株的获取和接受。这种伦理考虑可能会阻碍进展并限制细胞表达系统的选择。
全球细胞增殖市场趋势
研究人员和科学家正在积极研究和开发创新的表现系统，作为解决传统平台所带来的限制的手段。特别是，人们对无细胞表现系统越来越感兴趣，例如无细胞蛋白质合成（CFPS），其具有不依赖完整细胞即可产生蛋白质的优势。此外，合成生物学技术被用来增强工程细胞株的表达能力并优化蛋白质生产效率。
目录
- 执行摘要
- 调查方法
- 母市场分析
- 主要市场考察
- 技术分析
- 价格分析
- 供应链分析
- 价值链分析
- 市场生态系统
- 智慧财产权分析
- 贸易分析
- Start-Ups分析
- 原料分析
- 创新矩阵
- 研发线产品分析
- 总体经济指标
- 主要投资分析
- 关键成功因素
- 竞争程度
- 市场动态及展望
- 市场动态
- 促进因素
- 机会
- 抑制因素
- 任务
- 监管形势
- 波特的分析
- 对未来中断的特殊考虑
- 市场动态
- 全球细胞增生市场：按产品
- 市场概况
- 消耗品
- 培养瓶及配件
- 装置
- 全球细胞增生市场：依细胞类型
- 市场概况
- 哺乳动物的
- 微生物
- 其他的
- 全球细胞增生市场规模：按地区
- 市场概况
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲国家地区
- 亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 其他拉丁美洲地区
- 中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区
- 竞争形势
- 前5名企业对比
- 主要企业市场定位（2021年）
- 主要市场参与者所采取的策略
- 关键成功策略
- 近期市集活动
- 主要企业市场占有率（2021年）
- 主要企业简介
- Thermo Fisher Scientific Inc.（United States）
- Merck KGaA（Germany）
- Lonza Group Ltd.（Switzerland）
- GE Healthcare（United States）
- Sartorius AG（Germany）
- Promega Corporation（United States）
- Agilent Technologies, Inc.（United States）
- Bio-Rad Laboratories, Inc.（United States）
- Eppendorf AG（Germany）
- Takara Bio Inc.（Japan）
- GenScript Biotech Corporation（China）
- CellGenix GmbH（Germany）
- BD Biosciences（United States）
- Novasep Holding SAS（France）
- OriGene Technologies, Inc.（United States）
- Lonza Biologics Plc（United Kingdom）
- Danaher Corporation（United States）
- Wuxi AppTec Co., Ltd.（China）
- Charles River Laboratories International, Inc.（United States）
- Miltenyi Biotec GmbH（Germany）
- New England Biolabs, Inc.（United States）
- Qiagen NV（Netherlands）
Global Cell Expansion Market size was valued at USD 25.21 billion in 2022 and is poised to grow from USD 27.60 billion in 2023 to USD 57.06 billion by 2031, growing at a CAGR of 9.5% during the forecast period (2024-2031).
One of the key drivers in the market stems from the increasing adoption of automated solutions in cell expansion applications, particularly in gene treatments, cell therapy products (CTP), and other biologics, resulting in cost and labor savings while enhancing procedural reliability. The shift towards Single-Use Systems (SUS) in CTP manufacturing brings significant production advantages by eliminating risks of cross-contamination and culture contamination due to inadequate sterilization, leading to long-term cost reductions and enabling the production of CTP with higher cell densities. This surge in SUS adoption stimulates the development of CTP, further propelling market expansion. Concurrently, the life sciences sector experiences a rising interest in cellular therapies, driven by augmented funding from commercial and public entities, along with their initiatives to foster cellular therapy advancements. Entities like the International Society for Stem Cell Research actively seek funding opportunities for stem cell-related research applications, anticipating substantial financial success for the market fueled by technological advancements and product innovations in cell expansion. However, a potential obstacle to market progression may arise from the scarcity of advanced instrumentation and 3D cell expansion technology.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Expansion Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Cell Expansion Market Segmental Analysis
Global Cell Expansion Market is segmented on the basis of product, end use, cell type and region. By product, the market is segmented into consumables, culture flasks & accessories, instruments. By end use, market is segmented into biopharmaceuticals, research institutions, cell banks, others. By cell type, the market is segmented into mammalian, microbial, others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Cell Expansion Market
The ongoing progress in genetic engineering, notably exemplified by CRISPR/Cas9, has streamlined the creation of superior cell lines tailored for efficient protein expression. These cutting-edge tools empower exact adjustments to cell genomes, enhancing protein yields, refining cellular processes, and elevating product standards. The existence of meticulously characterized and exceptionally productive cell lines significantly bolsters the expansion of the cell expression sector.
Restraints in the Global Cell Expansion Market
The creation of cell lines for expression systems frequently relies on animal or human-derived cells, leading to ethical dilemmas. Concerns over animal rights, ethically sourcing human cells, and the use of embryonic stem cells can constrain the accessibility and acceptance of specific cell lines. These ethical considerations have the potential to impede advancement and narrow the options for cell expression systems.
Market Trends of the Global Cell Expansion Market
Researchers and scientists are actively investigating and advancing innovative expression systems as a means to address the constraints posed by conventional platforms. Notably, there is a growing interest in cell-free expression systems such as cell-free protein synthesis (CFPS), which offer the advantage of protein production without reliance on intact cells. Furthermore, synthetic biology techniques are being utilized to enhance expression capacities and optimize protein production efficiency in engineered cell lines.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Market Dynamics
- Global Cell Expansion Market by Product
- Market Overview
- Consumables
- Culture Flasks & Accessories
- Instruments
- Global Cell Expansion Market by Cell Type
- Market Overview
- Mammalian
- Microbial
- Others
- Global Cell Expansion Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Group Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE Healthcare (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sartorius AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Promega Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eppendorf AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takara Bio Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GenScript Biotech Corporation (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CellGenix GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BD Biosciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novasep Holding S.A.S. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- OriGene Technologies, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Biologics Plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Wuxi AppTec Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories International, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Miltenyi Biotec GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- New England Biolabs, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Qiagen N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (United States)
